"The Report
OpportunityAnalyzer: Myelofibrosis - Opportunity Analysis and
Forecasts to 2025 provides information on pricing, market analysis,
shares, forecast, and company profiles for key industry participants.
- MarketResearchReports.biz"
Myelofibrosis
(MF) is a rare blood disorder, which is characterized by bone marrow
fibrosis. Currently, there is only one approved drug, Incyte/Novartis
Jakafi (ruxolitinib), for the treatment of MF, and other conventional
therapies used in MF are off-label. However, none of these drugs are
curative, and the only potentially curative intervention is
allogeneic stem cell transplant (allo-SCT), which is available to a
very small percentage of eligible patients because of the high risk
of morbidity and mortality. Therefore, there is a huge unmet need for
the treatment of MF.
This
report highlights the significant unmet need for novel drug treatment
for MF, both to alleviate MF-associated complications and to reverse
the disease course, across the seven major markets; it also discusses
the associated commercial opportunities for new market entrants to
gain a foothold in the market. GlobalData anticipate the MF market to
almost double, from $545.2m to $1.01 billion, over the forecast
period of 2015-2025. The key drivers wills be the launch of pipeline
drugs, increasing incidence and an increase in the use of drugs for
splenomegaly and constitutional symptoms in the 5EU and Japan.
View
Report @ http://www.marketresearchreports.biz/analysis/959624
Highlights
Key Questions Answered
- The MF market has high unmet
need. What are the main unmet needs in this market? How will the
drugs under development fulfil the unmet needs of the MF market?
- There are three middle- to
late-stage MF pipeline drugs expected to launch during the forecast
period. Will these drugs make a significant impact on the MF market?
Which of these drugs will have the deepest patient penetration and
highest peak sales, and why?
- The current MF market is
dominated by one JAK inhibitor, Jakafi. How will the launch of
pipeline drugs with novel mechanism of action change this? How will
the way MF patients are treated change over the next years? What are
the key drivers and barriers to this change?
Key Findings
- The launch of premium priced
products, in particular second-line treatments for patients who are
refractory to Jakafi, will be the main drivers of growth in he MF
market.
- There are high unmet needs in
MF. The biggest unmet need is for curative treatments. The unmet
needs will only be partially addressed by the major pipeline drugs.
In addition, there are currently no approved or major pipeline drugs
for MF-associated anemia. Any drug that can get approved in this
setting can expect a lucrative return.
- Key Opinion Leaders urged pharma
companies to focus their R&D strategies on trying to reverse the
disease course of MF. This will involve collaborating with academics
to identify new molecular targets.
- One key R&D strategy will be
developing drugs that reverse bone marrow fibrosis.
Get
Sample Copy Of This Report @
Scope
-
Overview of MF, including epidemiology, etiology, pathophysiology,
symptoms, diagnosis, treatment guidelines and disease management.
-
Annualized MF therapeutics market revenue, average cost of therapy
and treatment usage pattern data from 2015 and forecast for seven
years to 2025.
-
Key topics covered include strategic competitor assessment, market
characterization, unmet needs, clinical trial mapping and
implications for the MF therapeutics market.
-
Pipeline analysis: comprehensive data split across different phases,
emerging novel trends under development, and detailed analysis of
middle- to late-stage pipeline drugs.
-
Analysis of the current and future market competition in the global
MF therapeutics market. Insightful review of the key industry
drivers, restraints and challenges. Each trend is independently
researched to provide qualitative analysis of its implications.
Reasons to buy
The
report will enable you to -
-
Develop and design your in-licensing and out-licensing strategies
through a review of pipeline products and technologies, and by
identifying the companies with the most robust pipeline. Additionally
a list of acquisition targets included in the pipeline product
company list.
-
Develop business strategies by understanding the trends shaping and
driving the global MF therapeutics market.
-
Drive revenues by understanding the key trends, innovative products
and technologies, market segments, and companies likely to impact the
global MF therapeutics market in future.
-
Formulate effective sales and marketing strategies by understanding
the competitive landscape and by analysing the performance of various
competitors.
-
Identify emerging players with potentially strong product portfolios
and create effective counter-strategies to gain a competitive
advantage.
-
Track drug sales in the global MF therapeutics market from 2015-2025.
-
Organize your sales and marketing efforts by identifying the market
categories
Table of Contents
1 Table of Contents 9
1.1 List of Tables 14
1.2 List of Figures 17
2 Introduction 19
2.1 Catalyst 19
2.2 Related Reports 19
2.3 Upcoming Related Reports 20
3 Disease Overview 21
3.1 Etiology and Pathophysiology
21
3.1.1 Etiology 22
3.1.2 Pathophysiology 23
3.2 Classification and Prognosis
25
3.3 Symptoms 27
3.4 Quality of Life 30
4 Epidemiology 31
4.1 Risk Factors and Comorbidities
32
4.2 Global Trends 34
4.2.1 US 35
4.2.2 5EU 37
4.2.3 Japan 37
4.3 Forecast Methodology 37
4.3.1 Sources Used 37
4.3.2 Forecast Assumptions and
Methods 48
4.3.3 Sources Not Used 61
4.4 Epidemiological Forecast of
Myelofibrosis (2015-2025) 62
4.4.1 Diagnosed Incident Cases 62
4.4.2 Diagnosed Prevalent Cases 77
4.5 Discussion 90
4.5.1 Epidemiological Forecast
Insight 90
4.5.2 Limitations of the Analysis
91
4.5.3 Strengths of the Analysis 92
5 Current Treatment Options 93
5.1 Overview 93
5.2 Diagnosis and Treatment 94
5.2.1 Diagnosis 94
5.2.2 Treatment Guidelines and
Leading Prescribed Drugs 99
5.2.3 Clinical Practice 100
5.3 Major Brands - JAK Inhibitors
108
5.3.1 Jakafi (Ruxolitinib) 108
5.4 Conventional Medical Therapy
(Off-Label) 120
5.4.1 Cytoreductive Drugs 120
5.4.2 Androgen Therapies 121
5.4.3 Erythropoiesis-Stimulating
Agents 124
5.4.4 Immunomodulatory Imide Drugs
124
5.4.5 Anti-fibrotic Agents 126
6 Unmet Needs Assessment and
Opportunity Analysis 127
6.1 Overview 127
6.2 Development of Curative
Treatments 128
About us
MarketResearchReports.biz
is the most comprehensive collection of market research reports.
MarketResearchReports.Biz services are specially designed to save
time and money for our clients. We are a one stop solution for all
your research needs, our main offerings are syndicated research
reports, custom research, subscription access and consulting
services. We serve all sizes and types of companies spanning across
various industries.
Contact
Mr.
Nachiket
State
Tower
90
Sate Street, Suite 700
Albany,
NY 12207
Tel:
+1-518-621-2074
No comments:
Post a Comment